Column chart showing worldwide prescription-drug sales potentially at risk from patent expiration from 2026 through 2032. Sales at risk are $43 billion in 2026, $44 billion in 2027, $99 billion in 2028, $74 billion in 2029, $46 billion in 2030, $158 billion in 2031 and $63 billion in 2032. The largest annual exposure in the forecast is 2031.